FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898599058> ?p ?o ?g. }

• W2898599058 endingPage "viii679" @default.
• W2898599058 startingPage "viii679" @default.
• W2898599058 abstract "Background: Hepatocellular carcinoma (HCC) is the most common primary liver cancer. The recurrence rate after hepatectomy remains high, which seriously affects the prognosis. Microvascular invasion (MVI) has been proved to be an independent risk factor for the recurrence of liver cancer. If patients with MVI can receive timely and effective treatment, it will help reduce the recurrence rate, and prolong the survival time. The aim of the study was to analyze the effect of sorafenib on the clinical outcomes in HCC patients with MVI after hepatectomy. Methods: Patients with HCC who underwent hepatectomy and were pathologically diagnosed as MVI at the research center between January 2009 and December 2016 were retrospectively analyzed. Patients were divided into sorafenib group and control group according to whether or not sorafenib (Nexavar®) was taken after surgery. Sorafenib was administered orally, 0.4 g each time, twice daily. Follow-up was performed after hepatectomy. The recurrence-free survival (RFS) and overall survival (OS) were observed. Associated factors were analyzed using univariate and multivariate COX regression. Results: This study included 16 patients in the sorafenib group and 33 patients in the control group. There was no significant difference in age, gender, hepatitis B surface antigen level, preoperative prethrombin time (PT), BCLC stage, preoperative a-fetoprotein level, maximum tumor diameter, and tumor number (all P < 0.05). The RFS and OS were both longer in the sorafenib group (both P < 0.05). The three-year RFS rates of the sorafenib group and the control group were 9 (56.3%) and 8 (24.2%), respectively, with significant difference (P = 0.027). The three-year OS rates of the sorafenib and control group were 13 (81.3%) and 13 (39.4%), respectively, with significant differences (P = 0.006). The results of multivariate COX regression indicated that preoperative PT and sorafenib treatment were the independent associated factors for RFS and OS. Conclusions: The use of sorafenib after hepatectomy in HCC patients with MVI can prolong survival time. Legal entity responsible for the study: Zhiming Wang. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest." @default.
• W2898599058 created "2018-11-02" @default.
• W2898599058 creator A5018128086 @default.
• W2898599058 creator A5021354721 @default.
• W2898599058 creator A5025158403 @default.
• W2898599058 creator A5052120427 @default.
• W2898599058 creator A5073525246 @default.
• W2898599058 creator A5090239333 @default.
• W2898599058 date "2018-10-01" @default.
• W2898599058 modified "2023-10-17" @default.
• W2898599058 title "Survival analysis of sorafenib in hepatocellular carcinoma patients with microvascular invasion after hepatectomy" @default.
• W2898599058 doi "https://doi.org/10.1093/annonc/mdy304.033" @default.
• W2898599058 hasPublicationYear "2018" @default.
• W2898599058 type Work @default.
• W2898599058 sameAs 2898599058 @default.
• W2898599058 citedByCount "0" @default.
• W2898599058 crossrefType "journal-article" @default.
• W2898599058 hasAuthorship W2898599058A5018128086 @default.
• W2898599058 hasAuthorship W2898599058A5021354721 @default.
• W2898599058 hasAuthorship W2898599058A5025158403 @default.
• W2898599058 hasAuthorship W2898599058A5052120427 @default.
• W2898599058 hasAuthorship W2898599058A5073525246 @default.
• W2898599058 hasAuthorship W2898599058A5090239333 @default.
• W2898599058 hasBestOaLocation W28985990581 @default.
• W2898599058 hasConcept C126322002 @default.
• W2898599058 hasConcept C141071460 @default.
• W2898599058 hasConcept C143998085 @default.
• W2898599058 hasConcept C144301174 @default.
• W2898599058 hasConcept C159110652 @default.
• W2898599058 hasConcept C2776231280 @default.
• W2898599058 hasConcept C2776909242 @default.
• W2898599058 hasConcept C2777546739 @default.
• W2898599058 hasConcept C2778019345 @default.
• W2898599058 hasConcept C2778695046 @default.
• W2898599058 hasConcept C38180746 @default.
• W2898599058 hasConcept C50382708 @default.
• W2898599058 hasConcept C71924100 @default.
• W2898599058 hasConcept C90924648 @default.
• W2898599058 hasConceptScore W2898599058C126322002 @default.
• W2898599058 hasConceptScore W2898599058C141071460 @default.
• W2898599058 hasConceptScore W2898599058C143998085 @default.
• W2898599058 hasConceptScore W2898599058C144301174 @default.
• W2898599058 hasConceptScore W2898599058C159110652 @default.
• W2898599058 hasConceptScore W2898599058C2776231280 @default.
• W2898599058 hasConceptScore W2898599058C2776909242 @default.
• W2898599058 hasConceptScore W2898599058C2777546739 @default.
• W2898599058 hasConceptScore W2898599058C2778019345 @default.
• W2898599058 hasConceptScore W2898599058C2778695046 @default.
• W2898599058 hasConceptScore W2898599058C38180746 @default.
• W2898599058 hasConceptScore W2898599058C50382708 @default.
• W2898599058 hasConceptScore W2898599058C71924100 @default.
• W2898599058 hasConceptScore W2898599058C90924648 @default.
• W2898599058 hasLocation W28985990581 @default.
• W2898599058 hasOpenAccess W2898599058 @default.
• W2898599058 hasPrimaryLocation W28985990581 @default.
• W2898599058 hasRelatedWork W1992278374 @default.
• W2898599058 hasRelatedWork W2072645058 @default.
• W2898599058 hasRelatedWork W2361700749 @default.
• W2898599058 hasRelatedWork W2790326980 @default.
• W2898599058 hasRelatedWork W2803598729 @default.
• W2898599058 hasRelatedWork W2810368050 @default.
• W2898599058 hasRelatedWork W3009075395 @default.
• W2898599058 hasRelatedWork W3034258804 @default.
• W2898599058 hasRelatedWork W3215463326 @default.
• W2898599058 hasRelatedWork W4308722554 @default.
• W2898599058 hasVolume "29" @default.
• W2898599058 isParatext "false" @default.
• W2898599058 isRetracted "false" @default.
• W2898599058 magId "2898599058" @default.
• W2898599058 workType "article" @default.